Incremental Expenditure of Treating Hypertension in the United States

Abstract

With incremental direct medical expenditures estimated at nearly 55.0 billion US dollars, hypertension expenditures represent a significant amount of health care resource use.

The regulation of salt transport and blood pressure by the WNK-SPAK/OSR1 signalling pathway

“…In 2001, in the USA alone, the cost of treating hypertension and its resulting complications was estimated to have been $54 billion (Balu and Thomas, 2006). Although hypertension can be moderated by lifestyle changes, in most patients the use of various drugs is required to lower blood pressure significantly.…”

Prevalence of self-reported arterial hypertension in Brazilian capitals in 2011 and analysis of its trends in the period between 2006 and 2011

“…The World Health Organization (WHO) estimates that approximately 25% of the population have arterial hypertension (AH), and an increase of 60% is predicted for 2025 1,4 . Besides, AH brings high socioeconomic costs, and directly affects individuals, the health system and the economy 5 . Risk factors associated with AH are described in literature, such as inadequate diet, excessive salt, abusive alcohol consumption, physical inactivity, excess weight, smoking, glucose and lipid metabolism disorders [3][4][5][6][7] .…”

“…Besides, AH brings high socioeconomic costs, and directly affects individuals, the health system and the economy 5 . Risk factors associated with AH are described in literature, such as inadequate diet, excessive salt, abusive alcohol consumption, physical inactivity, excess weight, smoking, glucose and lipid metabolism disorders [3][4][5][6][7] . In Brazil, there are a few population based studies referring to the prevalence of AH.…”

Review: Hypertension, a health economics perspective

“…Prescription medicines, inpatient visits and outpatient visits comprised more than 90% of the overall incremental cost of treating hypertension. With hypertension affecting approximately 17.4% of the population in 2001, and incremental direct medical costs estimated at nearly US$55.0 bn for the year 2001, the costs of treating hypertension represent a significant economic burden [Balu and Thomas, 2006].…”